Drug resistance in DNA repair defective ovarian cancer

DNA修复缺陷卵巢癌的耐药性

• 批准号: nhmrc : 1076048
• 负责人: Dr Alison Hadley
• 金额: $ 8.14万
• 依托单位: The Walter and Eliza Hall Institute of Medical Research
• 依托单位国家: 澳大利亚
• 项目类别: NHMRC Postgraduate Scholarships
• 财政年份: 2014
• 资助国家: 澳大利亚
• 起止时间: 2014-01-01 至 2016-12-31
• 项目状态: 已结题
• 来源: https://researchdata.edu.au/drug-resistance-dna-ovarian-cancer/455710
• 关键词: Drug; resistance; DNA; repair; defective

Ovarian cancer is a major cause of cancer death in women because current treatments are inadequate. Half of aggressive ovarian cancers have abnormalities in DNA repair and respond to new PARP inhibitor therapy, yet even then the cancer often recurs. I will use a new model to study human ovarian cancers in mice. My focus will be understanding resistance to PARP inhibitors in individual ovarian cancers and designing approaches to overcome this resistance.

卵巢癌是女性癌症死亡的主要原因，因为目前的治疗方法不足。一半的侵袭性卵巢癌在DNA修复方面存在异常，并对新的PARP抑制剂治疗有反应，但即使如此，癌症也经常复发。我将使用一种新的模型来研究小鼠的人类卵巢癌。我的重点将是了解个体卵巢癌对PARP抑制剂的耐药性，并设计克服这种耐药性的方法。